Abstract

Objective The objective of this study was to examine the clinicopathologic correlates of T-regulatory (T reg) cell infiltration in serous ovarian cancers and to define gene signatures associated with high T regs. Methods Tumor infiltrating T reg and cytotoxic T-cells (CTLs) were quantitated in 232 primary serous ovarian cancers by immunostaining for FOXP3 and CD8. Expression microarray analysis was performed in a subset of 48 advanced cancers with the highest and lowest numbers of infiltrating T regs and a genomic signature was developed using binary regression. ANOVA analysis was performed to assess the most differentially expressed genes and these genes were further assessed using Ingenuity Pathway Analysis (IPA) software. Results High T reg infiltration in ovarian cancers was associated with high grade ( p < 0.0001), advanced stage ( p = 0.004) and suboptimal debulking ( p < 0.04), but not with survival. In contrast, high tumor infiltrating CD8 CTL infiltration was associated with favorable survival (median survival 48.7 vs. 34.6 months, p = 0.01). A microarray-based genomic signature for high tumor-infiltrating T reg cells had a 77% predictive accuracy using leave-one-out cross-validation. ANOVA of microarray data revealed the antigen presentation pathway as the most differentially expressed canonical pathway ( p < 0.00001) between cancers with high and low T reg cells. Conclusions These data suggest that there may be an association between increased T reg cell infiltration in ovarian cancers and advanced stage. Increased T reg infiltration is characterized by a genomic signature enriched with several immunologic pathway genes. Therapeutic strategies that reduce tumor infiltrating T reg cells are under investigation and may prove useful in ovarian cancers with high numbers of these cells.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.